Imperial College London Centenary
 
About Imperial
About ImperialContacts/getting hereAlumniResearchCoursesAbout this site
Select your text size  for this site here: Small Text Normal Text Large Text Extra Large Text

Note: Some of the graphical elements of this site are only visible to browsers that support accepted web standards. The content of this site is, however, accessible to any browser or Internet device.

 

New treatment that boosts the stomach's 'full' signal offers new way of tackling growing obesity epidemic


See also...
External Sites:
-Hammersmith Hospital NHS Trust
-Wellcome Trust
-Medical Research Council
(Imperial College is not responsible for the content of these external internet sites)

Imperial College London and Hammersmith Hospitals NHS Trust News Release

Under embargo for
00.01 BST
Monday 25 July 2005

A hormone found in the small intestine has provided a crucial breakthrough in developing new drugs to tackle the growing obesity epidemic, claim scientists. Obesity now affects more than half of all UK adults, costing the UK up to £3.7 billion a year in sickness absence and treatments.

In an article published today in Diabetes, the world's top diabetes research journal, a team from Imperial College London and Hammersmith Hospitals NHS Trust has used injections of oxyntomodulin, a naturally occurring digestive hormone found in the small intestine, to reduce body weight and calorific intake in overweight volunteers.

The injections boost existing levels of oxyntomodulin, normally released from the small intestine as food is consumed, signalling to the brain that the body is full and has had enough to eat.

Professor Steve Bloom, senior researcher at Imperial College London and Hammersmith Hospital, says: "The discovery that oxyntomodulin can be effective in reducing weight could be an important step in tackling the rising levels of obesity in society. Not only is it naturally occurring, so has virtually no side effects, it could be ideal for general use as it can be self administered. Despite this, we still need to conduct larger clinical trials to test its effectiveness over longer periods."

The researchers found that over four weeks, injections of oxyntomodulin three times a day in 14 volunteers reduced their body weight by an average of 2.3kg. They also found that daily energy intake by the test group was reduced by an average of 170kcal after the first injection, to 250kcal at the end of four weeks. The average recommended intake is 2500 kcal per day for men, and 1940 for women.

The researchers also found that volunteers in the study group had lesser appetites without a reduction in food palatability.

Professor Bloom adds: "Obesity is fast becoming one of the biggest problems in society, affecting huge numbers in the western world, and with the latest figures showing 65 percent of American adults are overweight we desperately need new solutions. A reduction of up to ten percent in calorific intake would make a huge difference to the overweight, vastly improving their health. Obesity is well known as a major risk factor in all sorts of conditions, including coronary heart disease, cancer, and the development of late onset diabetes."

The team looked at 26 volunteers over a four week period in a double blind randomised trial. The treatment group of 14 self administered oxyntomodulin 30 minutes before each meal, three times a day, over a period of four weeks. The control group of 12 volunteers administered saline at the same frequency for the same period.

The study found that leptin, a protein responsible for regulating the body's energy expenditure was reduced in the study group. They also found reduced levels of adipose hormones, a hormone which encourages the build up of adipose tissues, a type of tissue where fat cells are stored.

Professor Bloom has set up a spin-out company, Thiakis, to commercialise this discovery, and run further trials.

The study was funded through project grants with project grants from the Wellcome Trust and the Medical Research Council.

-ends-

For further information please contact:

Laura Gallagher/Tony Stephenson
Press Officer
Communications Division
Tel: +44 (0)20 7594 6702/6712
Mobile: +44 (0)7803 886248
E-mail: l.gallagher@imperial.ac.uk

Notes to editors:

1. Subcutaneous oxyntomodulin reduces body-weight in overweight and obese subjects: a double blind randomised controlled trial. Diabetes, Vol 54, August 2005.

2. Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality.
Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - underpinned by a dynamic enterprise culture.
Website: www.imperial.ac.uk

[up]